Trial
NCT03903640
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
NovoCure Ltd.
Condition
Melanoma With Brain Metastasis
Intervention
Optune
Why stopped
The study was terminated early on 03/09/2022 due to low accrual during the COVID-19 pandemic.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-07